|
Variables
|
Immunological failure
|
COR(95%CI)
|
AOR(95%CI)
|
P value
|
|---|
|
Yes
|
No
|
|---|
|
Age
|
18–29
|
13 (24.1%)
|
41 (75.9%)
|
2.58 (0.95–7.04)
|
0.96 (0.25–3.66)
|
0.955
|
|
30–39
|
18 (10.7%)
|
151 (89.3%)
|
0.97 (0.39–2.45)
|
0.74 (.26–2.09)
|
0.570
|
|
40–49
|
18 (13.2%)
|
118 (89.3%)
|
1.23 (0.49–3.14)
|
1.19 (0.43–3.34)
|
0.731
|
|
> = 50
|
7 (10.9%)
|
57 (89.1%)
| | |
Ref
|
|
Educational status
|
Illiterate
|
18 (14.9%)
|
103 (85.1%)
|
2.33 (0.65–8.34)
|
2.05 (0.53–7.92)
|
0.297
|
|
primary school
|
17 (14.5%)
|
100 (85.5%)
|
2.27 (0.63–8.16)
|
2.14 (0.57–0.14)
|
0.265
|
|
secondary school
|
18 (12.7%)
|
124 (87.3%)
|
1.94 (0.54–6.91)
|
1.55 (0.41–5.94)
|
0.522
|
|
Tertiary
|
3 (7.0%)
|
40 (93.0%)
| | |
Ref
|
|
Duration on ART in year
|
<=6
|
30 (18.5%)
|
132 (81.5%)
|
2.05 (1.16–3.62)
|
2.07 (1.11–3.87)
|
0.023*
|
|
> 6
|
26(10%)
|
235 (90)%
| | |
Ref
|
|
Initial regimen
|
D4T + 3TC+ EFV
|
1 (3.4%)
|
28 (96.6%)
|
0.22 (0.03–1.77)
|
0.29 (0.04–2.49)
|
0.262
|
|
AZT +3TC + NVP
|
20 (12.8%)
|
136 (87.2%)
|
0.89 (0.41–1.98)
|
0.73 (0.28–1.92)
|
0.529
|
|
AZT + 3TC + EFV
|
2 (6.7%)
|
28 (93.3%)
|
0.44 (0.09–2.09)
|
0.46 (0.09–2.49)
|
0.370
|
|
TDF + 3TC + EFV
|
10 (11.5%)
|
77 (88.5%)
|
0.79 (0.32–1.98)
|
0.50 (0.16–1.59)
|
0.239
|
|
TDF + 3TC + NVP
|
6(19.4%)
|
25 (80.6%)
|
1.46(0.49–4.37)
|
0.99 (0.29–3.45)
|
0.996
|
|
D4T + 3TC + NVP
|
2 (33.3%)
|
4 (66.7%)
|
3.04 (0.49–18.67)
|
1.173 (0.18–7.49)
|
0.866
|
|
AZT+ 3TC + NVP(4c)
|
4 (66.7%)
|
2 (33.3%)
|
12.18 (1.99–74.67)
|
12.90 (1.17–142.67)
|
0.051
|
|
D4T + 3TC + NVP(4a)
|
11 (14.1%)
|
67 (85.9%)
| | |
Ref
|
|
Viral load
|
> = 20
|
33(28%)
|
82(72%)
|
4.987(2.775–8.963)
|
5.19 (2.81–9.62)
|
0.0001*
|
|
< 20
|
23(7%)
|
285(93%)
| | |
Ref
|
- Note:* Has significant association
- Those variables with in p value < 0.2 under bivariate analysis were included with in multivariate analysis
- COR crude odds ratio, AOR adjusted odds ratio, Ref reference, CI confidence interval, p significant value, D4T Stavudine, TDF TenofovirDisoproxilFumarate, AZT/ 3TC Zidovudine/Lamivudine, EFV Efavirenze, NVP Nevirapine
